GPhA Makes Spreadsheet Case For Patent Settlements After Legal Loss
Executive Summary
IMS report finds that 33 drugs launched prior to patent expiry as a result of patent settlements reduced drug costs by $25.5 billion from 2005 to 2012. But the selection of which settlements to calculate the savings from reveals the fundamental difference in perspectives between industry and FTC that remain in the wake of the Supreme Court ruling.